Skip to content Skip to left sidebar Skip to footer

Bulletin

New Vaccine Product Available for VFC/VFAAR

New Vaccine Product Available for VFC/VFAAR

A one-vial presentation of Menveo (MenACYW-135) is now available through the Philadelphia VFC & VFAAR programs. This presentation does not require reconstitution. The Prescribing Information now describes both presentations of Menveo: the current two-vial presentation and a new one-vial presentation. 

One-vial Presentation (NEW) 

  • NDC: 58160-0827-30 
  • For use in individuals 10 years through 55 years of age. 
  • The one-vial presentation contains Menveo in a single vial with a pink cap 
  • This presentation does not require reconstitution. 
  • Available to order for VFC and VFAAR. 

Two-vial Presentation

  • NDC: 58160-0955-09
  • For use in individuals with special medical conditions 2 months through 9 years of age going forward*
  • The two-vial presentation includes a vial with a gray cap containing the MenCYW-135 liquid conjugate component and a vial with an orange cap containing the MenA lyophilized conjugate component. The contents of the vials must be combined to form Menveo prior to administration. 
  • The two-vial presentation is no longer available through VFAAR. 
  • Providers with existing supply of the Menveo 2-vial presentation on hand may continue to administer the vaccine to indicated VFC-eligible patients aged 2 months – 18 years of age. Do not initiate returns of the Menveo 2-vial presentation until the vaccine expires. The Philadelphia VFC Program will not process returns of unexpired Menveo 2-vial vaccine.

*There is a limited supply of the two-vial presentation available through the VFC program. To ensure that vaccine is available for individuals 2 months of age through 9 years of age, plan to only use the two-vial presentation for individuals 2 months through 9 years of age. Order the one-vial presentation for individuals 10 years through 18 years of age. 

CPT/CVX Codes

The CPT and CVX code for the new presentation is the same as the old presentation:  

  • CPT: 90734 
  • CVX: 136

Resources

Sites using the two-vial presentation of Menveo you can now order the one vial presentation. Please make sure the Menveo, one-vial presentation, is added to your EHR before ordering. If you have any issues ordering, please reach out to our coordinators:

Thank you for keeping Philadelphia safe and healthy. If you have any questions, please email vaccines@phila.gov.

Please note, Menveo and Menquadfi are interchangeable. To change the formulation that your site orders, please complete the Change Request Form. Our team will review your request and reply with next steps. We recommend that sites that are part of a system or are affiliated use the same vaccine presentations across sites to ensure continuity of care and help prevent administration errors.

Urgent Update on COVID-19 Program

Urgent Update on COVID-19 Program

The Philadelphia Department of Public Health’s (PDPH) COVID-19 program is expected to end this Tuesday, 9/12 when full commercialization begins.

Any COVID-19 vaccine in your inventory received from PDPH will no longer be authorized for use. All remaining inventory must be reported as wastage and removed from both your PhilaVax and Vaccine Finder inventories. These doses should then be discarded following the guidelines used by your site.

Additionally, if you received a PDPH Digital Data Logger to monitor your COVID vaccine, we will be in contact to schedule a pick-up of this device.

Reporting of COVID Vaccine

With the commercialization of COVID-19 vaccine, please report the administration of these vaccines with your routine immunization data submissions to the Immunization Information System.

Bridge Access Program

As a reminder enrollment for the Bridge Access Program is live! If your patient population includes underinsured and uninsured individuals 19 years of age and older you may apply for pre-enrollment using the link below!

Bridge Access Program

Thank you!

We want to thank all sites for participating in the COVID-19 Vaccine Distribution Program. Through your hard work and diligent efforts we were able to vaccinate many Philadelphians and bring greater health to our residents.

Private COVID-19 Vaccine Procurement 

Private COVID-19 Vaccine Procurement 

Commercialization of COVID-19 vaccines is occurring next week. VFC Providers are required to match vaccines on the private side. We have created an FAQ to assist providers through this transition. 

Take these steps now to plan which COVID-19 vaccines you will purchase privately: 

  1. Review the anticipated presentations of vaccine products.
  2. Decide which products you plan to carry for your pediatric population. You may need to order more than one product to vaccinate all the children you see who are between 6 months – 18 years of age. You do not need to order multiple products for the same age group. 
  3. Establish relationships with manufacturer(s) for the vaccine products you plan to offer.

Review anticipated presentations of products

Establish relationships with manufacturers

Reach out to these pharmaceutical representatives to prepare your practice to order private stock of COVID-19 vaccine:

Once we have more information about VFC COVID-19 vaccine ordering, we will release resources and trainings to provide further guidance in this process.

New Vaccine Product Available Through VFC: Prevnar 20

New Vaccine Product Available Through VFC: Prevnar 20

On June 27, 2023, the CDC approved Prevnar 20 (PCV20) for use in pediatric patients. Beginning September 6, 2023, this Prevnar 20 is available to order for your VFC eligible patients. The Prevnar 13 (PCV13) is no longer available to order through the VFC program.

Sites using Prevnar 13 can now order Prevnar 20. Please make sure Prevnar 20 is added to your EHR before ordering.

Please note, Vaxneuvance and Prevnar 20 are interchangeable. To change the formulation that your site orders, please complete the Change Request Form. Our team will review your request and reply with next steps. We recommend that sites that are part of a system or are affiliated use the same vaccine presentations across sites to ensure continuity of care and help prevent administration errors.

Vaccine Change Request Form

Prevnar 20

PCV20 is now available through the Vaccines Children (VFC) program.

    • CVX code: 216
    • CPT code: 90677
    • NDC number: 00005-2000-10

For more information on Prevnar 20, review the package insert.

Additional resources:

FDA Prevnar 20 page
Immunize.org’s Ask the Experts 
VIS

Thank you for keeping Philadelphia safe and healthy. If you have any questions, please email vaccines@phila.gov.

 

Recap: RSV Immunization in Outpatient Settings 

Recap: RSV Immunization in Outpatient Settings

Thank you to those who attended the RSV townhall for nirsevimab (Beyfortus) immunization in outpatient settings on Tuesday, August 29! In case you missed it, please review important information below: 

Nirsevimab will be available to order through the Vaccines for Children (VFC) Program this fall. Here are some answers to relevant clinical questions: 

Do healthy infants need to be under 8 or 9 months at the time of injection?

Healthy infants need to be under 8 months of age at the time of injection.

What about infants who are at increased risk of severe RSV?
Children aged 8–19 months who are at increased risk of severe RSV disease entering their second RSV season should be immunized.

Any recommendations for co-administration of nirsevimab with COVID-19, flu, and routine vaccines?
Co-administration with other vaccines is acceptable.

Is there a patient information brochure to give to parents?
CDC will have an information sheet similar to a VIS which has not yet been released.

Can nirsevimab (Beyfortus) be administered when a child is ill?
It is up to the doctor’s discretion, and dependant on how ill the infant is.

Does an infant that gets palivizumab (Synagis) needs nirsevimab (Beyfortus)?
An infant that qualifies for palivizumab (Synagis) may need to get a dose if nirsevimab (Beyfortus) is unavailable. Once they receive their nirsevimab, they no longer need to get palivizumab.

View the MMWR and package insert here. Email victor.obeck@phila.gov for more information on ordering nirsevimab through the VFC Program. 

Integrating RSV Immunization into EHR Systems

Integrating RSV Immunization into EHR Systems

RSV immunization will be available to order through the Vaccines for Children (VFC) program this fall. This newly approved monoclonal antibody, nirsevimab (Beyfortus), will be used to protect newborns and infants born during or entering their first RSV season.

As your facility will likely administer this immunization, we are providing instructions for adding nirsevimab to your EHR system.

Please add nirsevimab to your EHR system. There are two versions of nirsevimab to account for two different doses. See the specifications below. The differences between the two are highlighted in green: 

Nirsevimab (Beyfortus) must be reported to PhilaVax in the same way as any other immunization. To accurately report eligibility and funding sources, HL7 messages for nirsevimab administration should adhere to the standard rules for VFC eligibility or ineligibility. 

If you are interested, you may work with PhilaVax staff individually to test nirsevimab HL7 messages and ensure complete reporting. To express interest in assistance with this process or for any questions, contact the immunization information system (IIS) interoperability coordinator at beweh.willor@phila.gov. 

Please forward this email to any additional contacts who need this information. If you are not the correct person to receive this email, reach out to beweh.willor@phila.gov with the correct contact information.

Recap: RSV Immunization in Inpatient Settings

Recap: RSV Immunization in Inpatient Settings

Thank you to those who attended the RSV townhall for nirsevimab (Beyfortus) immunization in inpatient settings on Friday, August 24! In case you missed it, please review important information below:

Nirsevimab will be available to order through the Vaccines for Children (VFC) Program this fall. Email victor.obeck@phila.gov to begin enrolling in the VFC Program today. 

RSV Townhall to Discuss Nirsevimab

RSV Townhall to Discuss Nirsevimab

Come learn about the newly approved monoclonal antibody, nirsevimab (Beyfortus), to prevent RSV in neonates and young infants at a townhall hosted by the Philadelphia Immunization Program. 

The townhall will take place over Zoom on Tuesday August 29 at 12pm.

Nirsevimab will be available to order through the VFC Program this fall. Prepare your practice for ordering and administration of the product at next week’s townhall. 

Register today!

View past email advisories and keep up with important events on our website. We look forward to seeing you soon!

VFC & VFAAR Flu Ordering Will Open 8/28/23

VFC & VFAAR Flu Ordering Will Open 8/28/23

VFC & VFAAR providers can order flu for the 2023-24 season starting Monday, 8/28/23. Make sure your site is ready!

  • Account for any unused 2022-23 VFC/VFAAR flu vaccine still at your site using PhilaVax:
    • Process a return for the unopened vials online in the Vaccines Returns module. A job aid with step by step instructions can be found here.
    • Complete an adjustment for any open MDVs in the Inventory Module. A job aid with step by step instructions can be found here.
    • Complete these steps today to avoid delays in processing your site’s 2023-24 flu season orders. If you have questions, contact DPHProviderHelp@phila.gov.
  • Order flu materials for your office. Get the conversation started about the importance of flu vaccination with these free posters.
  • Make sure that your EHR/EMR is set-up to report this year’s flu products. These are the vaccine available this year:

Visit our Flu Page on our website for more information on what vaccines are available and to gain access to flu resources and free print materials.